| HS Code | 525547 |
| Product Name | Yimuhong Perfusion Solution Veterinary Grade API |
| Product Type | Veterinary Active Pharmaceutical Ingredient (API) |
| Veterinary Grade | Veterinary Grade |
| Active Substance | Yimuhong Perfusion Solution active pharmaceutical substance |
| Intended Dosage Forms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Physical Format As Api | Fine powder marketed as veterinary-grade raw material for formulation |
| Color | Brown to yellowish-brown |
| Odor | Characteristic medicinal or herbal odor |
| Solubility | Water-soluble and suitable for reconstitution in aqueous solutions |
| Moisture Sensitivity | Moisture-sensitive; must be protected from humidity |
| Storage Conditions | Store in airtight, light-protected containers in a cool, dry place |
| Shelf Life | 24 months under recommended storage conditions |
| Quality Standard | Veterinary GMP-compliant product |
| Usage Purpose | Serves as an active pharmaceutical ingredient for compounding veterinary dosage forms |
As an accredited Yimuhong Perfusion Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in 25kg sealed drums, veterinary-grade Yimuhong Perfusion Solution API for tablets, injections, capsules, powders, granules, premix, and solutions. |
| Container Loading (20′ FCL) | Yimuhong veterinary API loaded in 20′ FCL, palletized, secured, moisture-protected, ventilated, temperature-controlled, ensuring safe, contamination-free transport. |
| Shipping | Shipped as a veterinary-grade API in sealed, inert containers with tamper-evident closures. Temperature-controlled transport maintains stability, with protection from moisture, light, and contamination. Full documentation—MSDS, Certificate of Analysis, and customs-compliant labeling—accompanies every order. Packaging is suitable for global freight, ensuring safe, compliant delivery to pharmaceutical facilities. |
| Storage | Store Yimuhong Perfusion Solution Veterinary Grade API in original, tightly closed containers, protected from light, moisture, and heat. Keep at a controlled room temperature (approximately 20–25°C); avoid freezing. Ensure area is clean and dry. Once the container is opened, use immediately and discard any unused portion. Keep out of reach of children and animals. |
| Shelf Life | Shelf life: 24 months in unopened, tightly sealed containers stored in a cool, dry, dark place. Use immediately after opening. |
In parenteral veterinary manufacturing, Yimuhong Perfusion Solution Veterinary Grade API is handled as a sterile-active candidate rather than a general chemical powder because the route of administration determines release specifications before formulation begins. At bulk release, the material is assayed by a validated high-performance liquid chromatography method, and the certificate of analysis records bacterial endotoxin below 0.25 EU/mg, sub-visible particulate matter consistent with Ph. Eur. 2.9.19, and a residue on ignition limit no greater than 0.1%. In a standard 500 L stainless steel compounding vessel, the API is dissolved in water for injection at 20–25 °C under nitrogen overlay; final active concentration is typically set between 0.2% w/v and 5.0% w/v, with the exact figure fixed by the target product profile and subsequent pH adjustment using 0.1 M hydrochloric acid or sodium hydroxide. If terminal sterilisation is selected, the filled type I glass vials are autoclaved at 121 °C for 15 min, provided forced degradation studies demonstrate assay loss below 5% and no unknown impurity above 0.2%; otherwise aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane is applied, with filter integrity testing performed before and after filling. At the filling line, residual dissolved oxygen is kept below 0.5 mg/L, and the solution is held at 25 ± 2 °C for no more than 8 h unless in-process stability data support a longer hold. The terminal product types include 50 mL and 100 mL single-dose vials, 250 mL multi-dose vials for large-animal use, and 500 mL polyolefin bags for intravenous infusion. Compliance for this route is governed by EU GMP Annex 1 (2022) sections on aseptic processing, Ph. Eur. 5.1.1 sterility, 2.6.14 bacterial endotoxin, and Regulation (EU) 2019/6 for veterinary medicinal products. Process boundaries include pH range 6.8–7.8 to avoid precipitation; published data for this specific configuration is limited when the API batch has particle size above D90 200 µm.
Where Yimuhong Perfusion Solution Veterinary Grade API is presented as a water-soluble powder for poultry, the critical point is not dissolution speed in the laboratory but recovery from in-line proportioners under variable water hardness and pH. Formulation uses a ribbon blender of 500–1000 L working volume, and the API is pre-blended with anhydrous dextrose and citric acid to a final active concentration of 1.0–10.0% w/w; final dosing in drinking water commonly corresponds to 0.1–1.0 g/L, adjusted by bodyweight. The dry blend is milled through a 0.8 mm screen and passed through a comil at 1500–3000 rpm, with final particle size target D90 180 µm to prevent proportioner clogging. Production-scale experience shows batch-to-batch content uniformity coefficient of variation remains below 5% only when the API is pre-milled to D90 < 120 µm and the blender fill level is maintained at 60–75% of nominal volume. The terminal product types are 100 g, 500 g, and 1 kg foil-lined sachets packed under nitrogen. Compliance obligations include VICH GL18 residual solvents, VICH GL11 impurities, Regulation (EU) 2019/6, and Ph. Eur. 2.9.40 uniformity of dosage units in single-dose sachets. The major limitation is that hard water with bicarbonate above 300 mg/L may depress recovery; liquid concentrates are not recommended for storage beyond 24 h if microbiological challenge data are absent.
Feed mill premix incorporation of Yimuhong Perfusion Solution Veterinary Grade API is treated as a low-moisture, high-dilution operation in which cross-contamination control defines layout. The API is first sifted through a 0.5 mm screen and stepwise diluted with lactose monohydrate or maize starch in a paddle mixer; target premix active loading is between 1.0% w/w and 10.0% w/w, with complete feed inclusion calculated to deliver 5–50 mg/kg bodyweight or as prescribed, requiring a letdown of 2–10 kg premix per tonne of finished feed. Mixing time at 25–40 rpm for 10–15 min is validated by sampling 10 points with a coefficient of variation below 5%. The terminal product types include 20 kg multiwall paper bags with a 0.1 mm polyethylene inner liner, or 25 kg drums for export. Compliance is framed by Directive 2002/32/EC on undesirable substances, FAMI-QS Code of Practice for specialty feed ingredients, and Regulation (EU) 2019/6 for medicated premix authorization. A documented hazard is carryover from paddle paddles and ribbon flights; validated cleaning using vacuum extraction and dry ice blasting must reduce cross-contamination below 0.1% of the lowest active batch. Do not mix this API directly with trace mineral premixes containing unbuffered copper sulfate or zinc sulfate; contact moisture above 2% w/w may initiate incompatibility and reduce assay recovery.
For companion-animal tablet and capsule lines, direct compression of Yimuhong Perfusion Solution Veterinary Grade API uses a binary filler system of microcrystalline cellulose and lactose monohydrate. The API load ranges from 5.0% w/w to 25.0% w/w, crospovidone is added at 2.0–5.0% w/w, and magnesium stearate at 0.5–1.0% w/w; total batch blending occurs in a 600 L V-blender at 10–15 rpm for 15 min. At pilot scale, a 10-station rotary tablet press with B tooling is operated at 8–20 kN compression force, tablet hardness controlled to 60–90 N, and friability below 0.8%. For capsule filling, the same dry blend is filled into size 3 hard gelatin capsules at 25 mg active fill weight using a semi-automatic capsule filler running at 4000–6000 capsules/h. The terminal product forms are 50 mg, 100 mg, and 250 mg scored tablets, and 25 mg hard gelatin capsules for oral administration to dogs and cats. Conformity is assessed by Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.3 content uniformity, USP <905> dosage unit uniformity, and Ph. Eur. 2.9.1 disintegration. Operational limitations are clear: if ejection force rises above 4.5 kN, tablet picking and sticking increase; pre-drying of API powder is required when ambient relative humidity exceeds 60%, and blending time beyond 25 min should be avoided to limit magnesium stearate over-lubrication.
| API load (% w/w) | MCC (% w/w) | Lactose monohydrate (% w/w) | Crospovidone (% w/w) | Mg stearate (% w/w) | Compression force (kN) | Hardness (N) | Friability (%) | Disintegration (s) |
|---|---|---|---|---|---|---|---|---|
| 5.0 | 42.5 | 47.5 | 4.0 | 1.0 | 8.5 | 62 | 0.72 | 145 |
| 10.0 | 40.0 | 45.0 | 4.0 | 1.0 | 11.0 | 74 | 0.58 | 168 |
| 15.0 | 37.5 | 42.5 | 4.0 | 1.0 | 14.5 | 82 | 0.44 | 180 |
| 25.0 | 32.5 | 37.5 | 4.0 | 1.0 | 19.0 | 95 | 0.31 | 210 |
Yimuhong Perfusion Solution Veterinary Grade API is incorporated into sterile perfusion solutions for equine, bovine, and porcine surgical protocols where extracellular electrolyte balance is maintained around physiological norm. The API is dissolved at 2.5–10.0 mmol/L in a balanced vehicle containing sodium 140–150 mmol/L, potassium 3.5–5.0 mmol/L, calcium 1.0–2.5 mmol/L, and chloride 100–110 mmol/L; final osmolality is adjusted with mannitol or glucose to 280–320 mOsm/kg, and pH is driven to 7.2–7.6 with bicarbonate or tromethamine. The process uses a jacketed stainless steel preparation vessel at 20–25 °C; the solution is passed through 0.45 µm pre-filtration and 0.22 µm polyethersulfone sterile filtration into 500 mL or 1000 mL PVC-free polyolefin bags, or 50 mL prefilled syringes. Final sterility is confirmed by Ph. Eur. 5.1.1 after terminal sterilisation at 115 °C for 20 min only if the forced degradation profile allows; otherwise aseptic filling is required, and the matrix must be protected with nitrogen overlay because dissolved oxygen above 0.5 mg/L accelerates oxidative degradation. Compliance for terminal product falls under Ph. Eur. 2.6.14 bacterial endotoxin limit <0.25 EU/mL, Ph. Eur. 2.6.14 sterility, EU GMP Annex 1 aseptic process requirements, and ISO 8536-4 for infusion equipment compatibility. Limitation: the solution must not be combined with calcium-containing additives before confirming compatibility; precipitation risk increases when phosphate is present above 1.0 mmol/L and pH exceeds 7.8.
In fluid-bed granulation for neonatal calves and foals, Yimuhong Perfusion Solution Veterinary Grade API is processed into oral granules by top-spray agglomeration rather than dry blending because the dosage form must reconstitute rapidly in milk or water without segregating. The dry binder is polyvinylpyrrolidone K30 at 2.0–5.0% w/w, the filler matrix is lactose monohydrate and microcrystalline cellulose at 60–80% w/w, and the API loading is 10.0–30.0% w/w; the granulating liquid is purified water or an ethanol-water mixture at 8–15% w/w of dry mass. In a 120 L fluid bed with top spray, inlet air is maintained at 55–65 °C, product temperature at 30–35 °C, spray rate at 20–50 g/min, and final moisture content is dried to 1.0–2.0% w/w before sifting through 1.0 mm and 0.5 mm meshes. The terminal product types are 1 g, 2.5 g, and 5 g aluminium foil sachets for reconstitution as an oral suspension, as well as 10 g multidose bottles. Conformity is assessed by Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.3 content uniformity, VICH GL18 residual solvents, and VICH GL11 degradation products; microbial quality follows Ph. Eur. 2.6.12 and 2.6.13. The main process limitation is nozzle blockage at spray rates below 15 g/min when binder viscosity exceeds 50 mPa·s; if the API is hygroscopic, finished sachet relative humidity must remain below 40% throughout packaging.
Competitive Yimuhong Perfusion Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Yimuhong Perfusion Solution Veterinary Grade API is supplied as a multi-presentation active pharmaceutical ingredient for tablets, injections, capsules, powders, granules, premixes, and solutions. The veterinary-grade designation is not a single physical form but a quality-system classification; the manufacturer releases separate internal grade codes for the sterile-filtered solution, lyophilized powder, micronized dry form, and granulated premix fraction. These grade codes appear on the certificate of analysis and are reconciled to receiving-site material codes. In solid oral and premix applications, the particle-size specification is typically set to a nominal D90 of 250 µm for direct compression or capsule filling and 500 µm for mineral or vegetable premix carriers. Dry forms are controlled to a residual moisture limit of ≤ 1.0% w/w unless a documented site-specific exemption is approved. For injection or solution applications, the parenteral grade is produced to a low-endotoxin and low-bioburden specification; sterility testing follows Ph Eur 2.6.1 or USP <71>, and subvisible particulate matter is evaluated by USP <788> for the finished injectable. Compared with bulk perfusion salts or organ-bath reagents, the product is defined by pharmaceutical change control, contaminant control, and dosage-form-neutral release specifications.
Exact numerical release values are batch-specific and must be taken from the current certificate of analysis. Published data for this specific configuration is limited where the manufacturer has not disclosed the full veterinary registration dossier. However, where parenteral administration is intended, a bacterial endotoxin acceptance criterion of < 0.25 EU/mg for lyophilized material or < 0.5 EU/mL for the reconstituted solution is commonly applied. The limit should be confirmed from the dose-based calculation specified in the relevant veterinary product registration. Residual solvents are controlled according to ICH Q3C, elemental impurities are assessed under ICH Q3D, and the manufacturing quality system is expected to follow ICH Q7 together with the applicable sections of 21 CFR 210/211.
The difference is operational rather than compositional. A research-grade perfusion salt may have a certificate of analysis limited to solubility, pH, and visual appearance; a feed additive may carry a heavy metal screen and a nutritional label claim but no pharmaceutical stability commitment. By contrast, the veterinary-grade API is maintained under a vendor change-control system that requires notification before changes in active ingredient source, milling, crystallization, drying, or packaging. Residual solvent class limits follow ICH Q3C, elemental impurities follow ICH Q3D, and the container closure system is qualified for the stated shelf life and transport. For sterile injectable development, the grade is supported by bioburden data before filtration, bacterial endotoxin release data, filter compatibility data, and container closure integrity testing. For solid oral and premix operations, the grade is linked to a defined particle-size distribution and drying history. This prevents the particle-size excursions and flow variability observed when an unqualified powder from a research supplier is substituted into a commercial tablet blend or mineral premix.
Another practical distinction appears in aqueous reconstitution. Reagent-grade material may contain insoluble particulates or elevated endotoxin that remain unnoticed in a non-pharmaceutical application. In an injectable or ophthalmic solution line, those particulates can raise subvisible particle counts beyond USP <788> limits for large-volume parenterals. The veterinary-grade form is filtered or processed to reduce such risk, but filtration is not automatically successful: membrane adsorption can reduce assay by 1–5% depending on the membrane polymer and the solution pH. Filter validation is therefore required for the exact solution matrix before routine manufacturing.
Dry blending and encapsulation operations are sensitive to the API particle-size distribution and electrostatic charge. In a ribbon blender with the chopper off at 25 rpm, an unmilled or highly aggregated fraction can segregate toward the top of the powder bed and create assay variability. A more reproducible approach is to pre-blend the API with a portion of lactose monohydrate for 10 min before adding the remaining excipients. The granulated premix form is intended for direct addition to a mineral or plant carrier. On a twin-screw wet granulation line with an L/D ratio of 25:1, the API can be dispersed in the binder solution rather than dry-fed into the throat when the target granule size is below 300 µm. This reduces nozzle blockage and local over-wetting but requires the API to remain chemically stable in the binder vehicle for the full spraying time. These processing observations reflect general pharmaceutical manufacturing practice rather than a published dossier for this exact product; receiving sites must confirm the site-specific ranges against the official specification.
Representative release parameters are shown below. The values are not a substitute for the batch-specific certificate of analysis; they illustrate the type of tests that should be present when a veterinary-grade multi-presentation API is purchased for solid oral, injectable, and premix formats. The manufacturer's registered limits may differ by species, dose, and pharmaceutical form.
| Quality attribute | Solid oral / capsule | Parenteral / injectable | Premix / granule | Reference method |
|---|---|---|---|---|
| Physical form | Micronized or granulated powder | Sterile-filtered solution or lyophilized cake | Granulated premix fraction | Visual, microscopy |
| Assay on dried basis | 98.0–102.0% | 95.0–105.0% for solution | 95.0–105.0% in matrix | Validated HPLC |
| Particle size | D90 ≤ 250 µm | Not applicable for solution; subvisible particulate per USP <788> | D90 ≤ 500 µm | Laser diffraction |
| Water content | ≤ 1.0% w/w | Lyophilized cake ≤ 3.0% w/w | ≤ 1.5% w/w | Karl Fischer |
| Bacterial endotoxin | Not routinely tested unless required by dose | < 0.25 EU/mg or < 0.5 EU/mL based on dose | Not routinely tested unless required by species | Ph Eur 2.6.14 |
| Sterility | Not sterile | Sterile per Ph Eur 2.6.1 or USP <71> | Not sterile | Membrane filtration |
| Elemental impurities | Assessed per ICH Q3D oral limits | Assessed per ICH Q3D parenteral limits | Assessed per ICH Q3D oral limits or species-specific VICH guidance | ICP-MS |
Process conflict emerges when the same API lot is considered for both a terminally sterilized injectable and a lyophilized vial. A heat-labile perfusion API cannot be sterilized at 121 °C for 15 min without risking degradation and visible particulate formation; in that case the injectable line must rely on aseptic filtration through a 0.22 µm sterilizing-grade membrane. The filter validation must quantify binding or adsorption losses on the membrane. If the active pharmaceutical ingredient is surface-active, the loss can exceed 5% and shift the finished solution assay outside the 95.0–105.0% target. For a lyophilized product, the cake moisture limit is typically held at ≤ 3.0% w/w; higher moisture depresses the glass transition temperature of the cake and can cause collapse during storage above 25 °C. Terminal sterilization of dry powder by dry heat is not compatible with low-melting or amorphous material unless the powder has been qualified for thermal stability under the registered cycle. This processing window is a critical threshold risk because a cycle deviation of ±5 °C in a dry-heat step may either fail sterility assurance or induce polymorphic transformation.
A sterile injectable lot should not be reverse-transferred into a non-sterile dry premix dispensing booth after the material has entered the classified aseptic filling area. Unidirectional flow is required under 21 CFR 211.67 and EU GMP Annex 1, because the movement of containers between classified and non-classified zones spreads particulate and microbial contamination. If the operation requires both presentations, separate lots should be planned at bulk stage. The dry grade can be handled in a contained dispensing suite with local exhaust ventilation and then blended into a mineral or vegetable carrier. The injectable grade is received into a sterilized vessel, filtered through a validated membrane, and filled under aseptic conditions. A recurring failure on production lines is the reuse of a transfer container across both streams without a validated cleaning procedure; detergent residues then enter the next batch and alter reconstituted pH. For high-volume premix lines, bulk density is usually specified between 0.45 g/mL and 0.65 g/mL, because lower values can create excessive dust and poor flow into volumetric auger filling equipment, while higher values may reduce blend uniformity in low-dose premixes.
The dry-powder presentation is not a single material with a single set of powder properties; the drying method changes downstream performance. Spray-dried material typically has lower bulk density and faster aqueous wetting than tray-dried material, but it may also contain a higher amorphous fraction. Amorphous content above approximately 10% w/w can absorb atmospheric moisture during storage and produce a sticky granulation end-point in high-shear mixers. For aqueous reconstitution, the pH and ionic strength of the reconstituted solution should be recorded because both affect the stability of the finished injectable and the loading of the active material onto a sterile diluent. During capsule filling, static charge can reduce weight uniformity when the spray-dried fraction is processed below 30% RH; a flow aid such as 0.5% w/w colloidal silicon dioxide or sodium stearyl fumarate may be introduced, but this addition must be pre-approved in the veterinary product dossier because it changes the quantitative formulation. The granulated premix form, by contrast, is optimized for direct carrier blending and usually has a lower surface area and a lower electrostatic tendency.
When Yimuhong Perfusion Solution Veterinary Grade API is dispersed in a vegetable or mineral carrier, the stability of the active ingredient is frequently controlled by the oxidative state of the carrier rather than by the API alone. A peroxide value below 5 meq O₂/kg and an anisidine value below 10 are commonly targeted for refined carrier oils before the API is added; higher values can generate free radicals that degrade the active molecule during storage. If the registered premix permits antioxidants, ethoxyquin or butylated hydroxytoluene may be included at levels that are controlled by the target species and the maximum residue limits. However, published data for this specific product configuration is limited, so the precise antioxidant system must be established through forced degradation and long-term stability studies. A common manufacturing failure is to add the API directly to warm carrier oil above 40 °C; oil oxidation accelerates, and the API may partition to the vessel wall or the headspace. For continuous premix lines, the API premix is usually added after the carrier has cooled to below 35 °C, and the mixer is blanketed with nitrogen if the carrier contains unsaturated fatty acids.
Cleaning validation for Yimuhong Perfusion Solution Veterinary Grade API in multi-product facilities is challenging because the analytical method must detect the active in powder, granule, and liquid residues. Swab limits are normally calculated from a health-based exposure assessment rather than simply from the 10 ppm criterion; the permitted carryover is expressed in mg of API per cm² of contact surface and must account for the smallest marketed veterinary dosage form. For a water-insoluble API, rinse sampling alone can miss residues adsorbed to gaskets or polytetrafluoroethylene seals. Equipment that contacts both the sterile solution and the dry powder grade requires dedicated or campaign-separated product-contact parts. If the facility uses shared milling equipment, the cleaning procedure should be validated with the actual micronized form because its high surface area can increase the mass remaining in dust-collection lines. These boundaries are part of the supplier's quality agreement and should be reviewed before bringing the product into a new line.
